Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Phase 2
Completed
- Conditions
- Cancer of the Pancreatic Head
- Registration Number
- NCT00490360
- Lead Sponsor
- University of Zurich
- Brief Summary
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.
- Detailed Description
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed.
Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.
* Trial with medicinal product
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2007
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Resectability rate > 70% after restaging 2007
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital of Zurich, Department of Surgery
🇨🇭Zurich, Switzerland